tert-Butyl ((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)carbamate

Catalog No. :
ACXEZF564
CAS No. :
2357114-90-8
Molecular Formula :
C19H23N3O5
Molecular Weight :
373.41

IUPAC Name:tert-butyl ((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)carbamate

tert-Butyl ((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)carbamate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
50mg97%$686.00Login to see priceInquiryInquiry
100mg97%$859.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Nametert-Butyl ((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)carbamate
IUPAC Nametert-butyl ((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)carbamate
MDL No.0
Molecular FormulaC19H23N3O5
Molecular Weight373.41
SMILESO=C(OC(C)(C)C)NCC1=CC2=C(C(N(C(CC3)C(NC3=O)=O)C2)=O)C=C1
InChI KeyKLJMOQDPIZUJLA-UHFFFAOYSA-N
Synonymtert-butyl N-{[2-(2,6-dioxopiperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-5-yl]methyl}carbamate;3-[5-[(Boc-amino)methyl]-1-oxoisoindolin-2-yl]piperidine-2,6-dione;Carbamic acid, N-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1-oxo-1H-isoindol-5-yl]methyl]-, 1,1-dimethylethyl ester
CAS No.2357114-90-8

Safety Data

Pictogram
ToxicHealth hazard
Signal Word
Gefahr
Hazard Statement(s)
H301-H312-H360
Precautionary Statement(s)
P201-P202-P264-P270-P280-P301+P310+P330-P302+P352+P312-P308+P313-P405-P501

Synthetic Route by SureRoute

1. ACXEZF564 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACXEZF564 route product structure diagram
    ACXEZF5642357114-90-8
Inquiry

2. ACXEZF564 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACXEZF564 route product structure diagram
    ACXEZF5642357114-90-8
Inquiry

Comments (0)